Key Details
Price
$59.18Annual ROE
-21.81%Beta
1.15Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 4, 2024Recent annual earnings:
Feb 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Verona Pharma (VRNA) might be a good option for investors interested in short-term gains from stocks that are fundamentally strong. It is among the stocks that have successfully met our criteria for short-term trading strategies.
Verona Pharma (VRNA) could see an increase in its stock price due to rising confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
If you're searching for stocks that are likely to keep rising, Verona Pharma (VRNA) might be a good option. It is among the stocks that have successfully gone through our "Recent Price Strength" filter.
Verona Pharma's new COPD treatment, Ohtuvayre, made $36 million in sales in the fourth quarter, showing a strong demand for new therapies. Even with its high price, Ohtuvayre's wide approval and strong interest from doctors suggest it could earn more than anticipated in annual sales. The company has $336 million in cash, which should support its operations until at least the end of 2026.
Net product sales of Ohtuvayre are expected to be around $36 million for the fourth quarter and about $42 million for the entire year of 2024.
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) has announced that its senior management will give a presentation about the company at several conferences in December 2024.
Verona Pharma's stock price has risen significantly as people look forward to the launch of its COPD treatment.
On November 5, 2024, Verona Pharma plc (Nasdaq: VRNA) announced that its senior management will give a presentation about the company at the Jefferies London Healthcare Conference. This event is scheduled for Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.
Verona Pharma plc (NASDAQ:VRNA) will hold its Q3 2024 Earnings Conference Call on November 4, 2024, at 9:00 AM ET. The call will feature key company leaders, including David Zaccardelli, the President and CEO, and Mark Hahn, the CFO. Several analysts from different firms will also participate in the call.
Ohtuvayre™ (ensifentrine) had net sales of $5.6 million in the third quarter, and sales in October were higher than those in Q3.
FAQ
- What is the ticker symbol for Verona Pharma?
- Does Verona Pharma pay dividends?
- What sector is Verona Pharma in?
- What industry is Verona Pharma in?
- What country is Verona Pharma based in?
- When did Verona Pharma go public?
- Is Verona Pharma in the S&P 500?
- Is Verona Pharma in the NASDAQ 100?
- Is Verona Pharma in the Dow Jones?
- When was Verona Pharma's last earnings report?
- When does Verona Pharma report earnings?
- Should I buy Verona Pharma stock now?